Study To Assess Efficacy and Safety of Oglemilast in Patients With Chronic Obstructive Pulmonary Disease (COPD)

PHASE2CompletedINTERVENTIONAL
Enrollment

427

Participants

Timeline

Start Date

May 5, 2008

Primary Completion Date

May 15, 2009

Study Completion Date

May 15, 2009

Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
DRUG

Oglemilast

Oglemilast low dose, oral administration, once daily for 12 weeks

DRUG

Placebo

Placebo, oral administration, once daily for 12 weeks

DRUG

Oglemilast

Oglemilast middle dose, oral administration, once daily for 12 weeks

DRUG

Oglemilast

Oglemilast high dose, oral administration, once daily for 12 weeks

Trial Locations (47)

11501

Forest Investigative Site, Mineola

14618

Forest Investigative Site, Rochester

14901

Forest Investigative Site, Elmira

18020

Forest Investigative Site, Bethlehem

19140

Forest Investigative Site, Philadelphia

22401

Forest Investigative Site, Fredericksburg

28207

Forest Investigative Site, Charlotte

29303

Forest Investigative Site, Spartanburg

29406

Forest Investigative Site, Charleston

29615

Forest Investigative Site, Greenville

32174

Forest Investigative Site, Ormond Beach

33155

Forest Investigative Site, Miami

33169

Forest Investigative Site, Miami

33316

Forest Investigative Site, Fort Lauderdale

33321

Forest Investigative Site, Tamarac

35215

Forest Investigative Site, Birmingham

43614

Forest Investigative Site, Toledo

45231

Forest Investigative Site, Cincinnati

45242

Forest Investigative Site, Cincinnati

47713

Forest Investigative Site, Evansville

48152

Forest Investigative Site, Livonia

55407

Forest Investigative Site, Minneapolis

55437

Forest Investigative Site, Edina

60076

Forest Investigative Site, Skokie

68046

Forest Investigative Site, Papillion

78229

Forest Investigative Site, San Antonio

79902

Forest Investigative Site, El Paso

80033

Forest Investigative Site WR1, Wheat Ridge

Forest Investigative Site WR2, Wheat Ridge

80112

Forest Investigative Site, Centennial

85006

Forest Investigative Site, Phoenix

85715

Forest Investigative Site, Tucson

90095

Forest Investigative Site, Los Angeles

90620

Forest Investigative Site, Buena Park

92024

Forest Investigative Site, Encinitas

92120

Forest Investigative Site, San Diego

92134

Forest Investigative Site, San Diego

92270

Forest Investigative Site, Rancho Mirage

92835

Forest Investigative Site, Fullerton

92868

Forest Investigative Site, Orange

95207

Forest Investigative Site, Stockton

97213

Forest Investigative Site, Portland

97504

Forest Investigative Site, Medford

98405

Forest Investigative Site, Tacoma

06708

Forest Investigative Site, Waterbury

02747

Forest Investigative Site, North Dartmouth

08003

Forest Investigative Site, Cherry Hill

Sponsors
All Listed Sponsors
lead

Forest Laboratories

INDUSTRY

NCT00671073 - Study To Assess Efficacy and Safety of Oglemilast in Patients With Chronic Obstructive Pulmonary Disease (COPD) | Biotech Hunter | Biotech Hunter